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Abstract
Aims: To investigate diabetic retinopathy screening attendance and trends in certified 
vision impairment caused by diabetic eye disease.
Methods: This was a retrospective study of attendance in three urban UK diabetic 
eye screening programmes in England. A survival analysis was performed to inves-
tigate time from diagnosis to first screen by age and sex. Logistic regression analysis 
of factors influencing screening attendance during a 15-month reporting period was 
conducted, as well as analysis of new vision impairment certifications (Certificate of 
Vision Impairment) in England and Wales from 2009 to 2019.
Results: Of those newly registered in the Routine Digital Screening pathway (n = 97 
048), 80% attended screening within the first 12 months and 88% by 36 months. Time 
from registration to first eye screening was longer for people aged 18–34 years, and 
20% were unscreened after 3  years. Delay in first screen was associated with in-
creased risk of referable retinopathy. Although 95% of participants (n = 291 296) 
attended during the 15-month reporting period, uptake varied considerably. Younger 
age, social deprivation, ethnicity and duration of diabetes were independent predic-
tors of non-attendance and referable retinopathy. Although the last 10 years has seen 
an overall reduction in vision impairment certification attributable to diabetic eye 
disease, the incidence of vision impairment in those aged <35 years was unchanged.
Conclusions: Whilst the majority of participants are screened in a timely manner, 
there is considerable variation in uptake. Young adults, have sub-optimal attendance, 
and levels of vision impairment in this population have not changed over the last 
10 years. There is an urgent need to explore barriers to/enablers of attendance in this 
group to inform policy initiatives and tailored interventions to address this issue.
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1 |  INTRODUCTION
The number of people with diabetes in the UK has more than 
doubled over the past two decades,1 with 3.8 million (~6%) 
of the population currently diagnosed with diabetes. Diabetic 
eye disease (comprising diabetic retinopathy and diabetic 
macular oedema) is a microvascular complication of type 1 
and type 2 diabetes mellitus. In 2012, a meta-analysis of 35 
population studies estimated the overall prevalence of any 
retinopathy in those with diabetes to be 35%, with a substan-
tially higher prevalence in those with type 1 diabetes.2
Despite the availability of effective treatments, dia-
betic eye disease remains one of the most common causes 
of certified blindness in people of working age in the UK 
and throughout the world.3,4 At the time of diagnosis of type 
2 diabetes some people already have referable diabetic eye 
disease. A significant proportion of vision loss is avoidable 
through early detection and timely treatment. Systematic 
screening for retinopathy for people with diabetes has long 
been endorsed as an important public health intervention.5 
Screening for sight-threatening retinopathy has been shown 
to be both clinically effective and cost-effective.6,7
In the UK, diabetic retinopathy screening is adminis-
tered by the National Screening Committee. In England, the 
National Diabetic Eye Screening Programme (NDESP) pro-
vides screening for all people with diabetes aged ≥12 years 
through 57 regional Diabetic Eye Screening Programme 
(DESPs). National programmes in Scotland, Wales and 
Northern Ireland serve the devolved administrations using a 
common national service specification. The NDESP uses an 
electronic system known as the ‘General Practice to Diabetic 
Retinopathy Screening’ that automatically shares informa-
tion between general practice databases and the local DESPs. 
Each screening programme receives a monthly list of those 
eligible for screening from general practices in their area. All 
new patients are invited for screening within 3 months of no-
tification. The majority of people are screened through the 
Routine Digital Screening pathway and are invited for annual 
screening with digital retinal photography. If sight-threat-
ening retinopathy is identified, then the person is either 
monitored more closely in a digital surveillance clinic, or is 
referred to the Hospital Eye Service for further assessment 
and possible treatment.
Given the importance of screening attendance for reduc-
ing the risk of sight loss amongst people with diabetes, it is 
essential that DESPs provide consistent and equitable access 
for the target population. The NDESP defines quality stan-
dards for diabetic eye screening8 that are monitored through 
the submission of quarterly and annual reports. The standards 
state that all newly diagnosed people with diabetes should be 
offered a screening appointment within 3 months and defines 
performance thresholds for screening uptake. The minimum 
acceptable standard is 75% uptake, with 85% considered to be 
achievable. Although the most recent annual data for England 
(2018–2019)9 reported an overall uptake of 83%, rates vary 
between programmes (range 74–92%). Previous research has 
identified a number of modifiable and non-modifiable risk 
factors associated with poor screening attendance including 
younger age, lower socio-economic status, type of diabetes, 
ethnicity, lack of awareness of the importance of screening 
and confusion between diabetic eye screening and routine eye 
care.10–14
Although type 1 is the predominant form of diabetes in 
young adults, the emerging epidemic of younger adults with 
type 2 diabetes15 presents a particular challenge. Despite im-
provements in disease management and shorter duration of 
diabetes, the incidence of sight-threatening retinopathy is sig-
nificantly higher in young adults with type 2 diabetes than in 
an age-matched control group with type 1 diabetes.16,17 The 
aim of the present study was to investigate the variability in 
uptake of first screening invitation across age groups within 
three large urban screening programmes in England and to 
explore the demographic factors that influence subsequent 
attendance. We also present a 10-year retrospective analysis 
of trends in vision impairment certifications attributable to 
diabetic eye disease in England and Wales by age.
2 |  PARTICIPANTS AND METHODS
A retrospective analysis of diabetic eye screening uptake was 
performed from anonymized data extracted from three urban 
regional screening programmes in England. We also under-
took a retrospective analysis of new certifications of sight 
impairment or severe sight impairment, where diabetic eye 
What's new?
• Improvements in diabetes care and the introduc-
tion of the National Health Service Diabetic Eye 
Screening Programme have led to a progressive 
decline in certified vision impairment caused by 
diabetic eye disease.
• The annual incidence of new certifications for vi-
sion impairment in young adults (age <35 years) 
has not seen the decline that has occurred in 
other age groups over the 10-year reporting pe-
riod. Although we cannot assume causality we 
also report sub-optimal screening uptake in this 
population.
• There is an urgent need to understand factors in-
fluencing retinopathy screening attendance in 
young adults to inform targeted interventions and 
policy initiatives to improve uptake.
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disease was the single main cause, for England and Wales, 
over a 10-year period from 2009 to 2019.
2.1 | Screening attendance across age groups
Data were extracted from three screening programmes: 
1) North East London; 2) South East London and; 3) 
Birmingham, Solihull and Black Country. These programmes 
serve an ethnically diverse population of over 300 000 people 
with diabetes, and include populations with higher than aver-
age levels of social deprivation.
Screening attendance was explored using two different 
approaches: i) time from registration with the screening 
programme to first screening attendance (Cohort A); and ii) 
screening uptake within a 15-month study period, to capture 
at least one screening episode during a ‘screening cycle’. 
Although a screening cycle takes just over 12  months, we 
extended the reporting period to 15 months to capture those 
invited at the end of the screening cycle (Cohort B).
Data were extracted from the OptoMize® (Northgate 
Public Services) screening software platform. For Cohort 
A, we obtained data on all newly registered participants who 
were eligible for the Routine Digital Screening pathway from 
1 January 2016 until 31 December 2018. Information on 
screening attendance was collected until 30 April 2019. This 
allowed a 40-month reporting period.
For Cohort B, data were collected from all participants 
who were on register on 1 February 2018 and eligible for 
the Routine Digital Screening pathway. Screening attendance 
was recorded for a 15-month period to 30 April 2019.
The following information was collected for both cohorts: 
sex; age; self-reported ethnicity (based on the 2001 UK cen-
sus standard for classifying the ethnic composition of the 
communities); type of diabetes; duration of diabetes; reti-
nopathy grading; and Index of Multiple Deprivation (IMD; 
linked from the participant's postcode by the screening pro-
gramme prior to providing the data). Based on the retinop-
athy grading, we defined ‘referable retinopathy’ as a grade 
requiring closer observation within the DESP through digi-
tal surveillance, or referral to an ophthalmologist. This was 
specified by the most severe retinopathy grade in either eye.
2.2 | Vision impairment certification
The registration process for certification as sight-impaired (par-
tially sighted) or severely sight-impaired (blind) in England 
and Wales involves the completion of a designated Certificate 
of Vision Impairment form. The form triggers a referral for 
a social care assessment if the individual is not yet known to 
social services. In addition, a copy of the form is sent to the 
Certifications Office, at Moorfields Eye Hospital, London for 
anonymized epidemiological research. Certification of vision 
impairment is dependent on specific visual acuity and field of 
vision criteria. Further details on the criteria used for certifica-
tion can be found in a recent publication.4 The total number 
of new certifications for sight impairment and severe sight 
impairment from 2009/2010 to 2018/2019 for England and 
Wales were recorded and the number of new certifications that 
had diabetic eye disease (including retinopathy and maculopa-
thy) as the main cause of certifiable vision impairment were 
documented. Annual population estimates based on the mid-
year estimates for England and Wales were obtained from the 
Office of National Statistics and used to calculate certification 
rates per 100 000 population.
2.3 | Statistical analysis
Participants’ demographic characteristics were analysed 
using descriptive statistics. For analysis of first screening 
attendance Kaplan–Meier plots were used to explore the 
proportion of people attending in each age strata at registra-
tion (12–17, 18–34, 35–59 and ≥60 years) against time from 
registration. Univariate and multiple fixed-effects logistic 
regression analysis was used to investigate the association 
between screening uptake and explanatory demographic fac-
tors including: age, sex, self-reported ethnicity and socio-
economic deprivation (IMD data were obtained using the 
postcode). The general practice code was included as a ran-
dom effect. Similarly, fixed effects logistic regression was 
used to identify risk factors associated with the detection of 
referable retinopathy. All data were processed and analysed 
using stata/ic 15.1 statistical software.
2.4 | Ethics
Analysis of anonymized data did not require ethical ap-
proval, but we obtained approval from each Research and 
Development Department of the National Health Service 
(NHS) Trusts providing data. All people in the Certificate of 
Vision Impairment dataset had provided explicit consent for 
anonymized data to be sent to the Certifications Office for 
research purposes.
3 |  RESULTS
3.1 | Screening attendance across age-groups
Age at registration, sex and postcode (for IMD analysis) 
are mandatory data fields and were available for almost all 
records. Ethnicity data were missing from 21% of records, 
type of diabetes for 35% and duration of diabetes for 45%. 
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For Cohort A, data from 97 048 newly registered partici-
pants were included in the analysis (Table 1). From this co-
hort 15 919 (16%) did not attend their first screening event 
within 40  months. Referable retinopathy was detected in 
approximately 3% of those screened. For the Kaplan–Meier 
analysis of time to first screening event, data were available 
for 1025 people aged 12–17 years, 8710 aged 18–34 years, 
50 928 aged 35–59  years and 36 385 aged ≥60  years. Of 
these, 78% of participants attended their first screening event 
within 6 months of registration, 80% by year 1 and 88% by 
3 years post-registration (Figure 1). Time to first screening 
was greater for participants aged 18–34 years at registration 
and 20% of this group had not attended screening at 3 years. 
The time to the first screening event was similar for men 
and women. Logistic regression analysis showed that people 
aged 18–34  years at registration were more likely to have 
referable retinopathy than those aged 35–59 years [odds ratio 
(OR) 1.26, 95% CI 1.10–1.45]. The longer the interval be-
tween registration and screening attendance, the more likely 
the individual was to have referable retinopathy [attendance 
at 12–35  months compared to attendance within 2  months 
(OR 1.83, 95% CI 1.57–2.13)].
For Cohort B, 291 296 people on screening registers 
and eligible for the Routine Digital Screening pathway 
were included in the analysis (Table 2). From this cohort, 
14 960 (5%) did not attend for screening during the 15-
month reporting period, with the remaining 276 335 (95%) 
attending. Data were excluded for one person, who at-
tended but left before screening could be performed. From 
those who attended a screening event, 93% were recalled 
for annual screening. Referable retinopathy was detected 
in 2.6%, who required either closer surveillance within the 
DESP or referral to ophthalmology. An urgent referral to 
the Hospital Eye Service was necessary for 0.2%. Ninety 
percent (260 633) of the cohort attended their first screen-
ing appointment within 15 months of registration with the 
DESP. There was significant variation in uptake among 
groups stratified by age (Figure 2), with 14% non-atten-
dance in those aged 24–29 and 30–35 years compared to 
4% non-attendance in those aged >60  years. Uptake was 
higher among people who had attended their first screen-
ing appointment within 15  months of initial registration, 
with only 3% of people who attended their first screening 
appointment not attending, compared to 24% who missed 
their first screening appointment.
The univariate analysis of Cohort B showed that the fol-
lowing factors were associated with screening attendance: 
age; sex; ethnicity; diabetes type; time from diagnosis of 
diabetes; IMD decile; and attendance for first screening 
appointment within 15  months of registration (Table 3). 
In terms of age, it was estimated that participants aged 
24–29  years were the least likely to attend compared to 
those aged ≥60  years (OR 0.25, 95% CI 0.22–0.29). The 
T A B L E  1  Demographic characteristics of newly registered people 
in the Routine Digital Screening pathway (Cohort A; N = 97 048).
Characteristic Missingness, n (%)
Mean (sd) age at registration, 
years
54.9 (15.4) -
Age at registration in groups n (%)
12–17 years 1025 (1.1) -
18–23 years 1269 (1.3)
24–29 years 2639 (2.7)
30–35 years 4802 (4.9)
36–41 years 8460 (8.7)
42–47 years 12 078 (12)
48–53 years 15 181 (16)
54–59 years 15 209 (16)
≥60 years 36 385 (38)
Total, N = 97 048
Sex n (%)
Female 41 422 (45) 4385 (4.5)
Male 51 227 (55)
Unknown 14 (0.0)
Total, N = 92 663
Ethnicity n (%)
White 31 360 (41) 20 446 (21.1)
Mixed 1533 (2.0)
Asian or Asian British 21 822 (29)
Black or Black British 13 472 (18)
Other/not stated/unknown 8415 (11)
Total, N = 76 602
National IMD decile groups 
(group 1 most deprived, 
group 4 least deprived)
n (%)
Group 1: (deciles 1–2) 41 949 (43) 319 (0.3)
Group 2 (deciles 3–4) 28 726 (30)
Group 3 (deciles 5–6) 13 454 (14)
Group 4: (deciles 7–10) 12 600 (13)
Total, N = 96 729
Diabetes type n (%)
Type 1 3209 (5.1) 34 192 (35.2)
Type 2 57 757 (92)
Not specified 1742 (2.8)
Other 148 (0.3)
Total, N = 62 856
Time from diagnosis of diabetes 
to registration
<5 years 48 011 (90) 43 661 (45.0)
5–9 years 2348 (4.4)
10–19 years 2209 (4.1)
≥20 years 819 (1.5)
Total, N = 53 387
Abbreviation: IMD, Index of Multiple Deprivation.
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association with age was still present after adjusting for all 
other factors (adjusted OR 0.31, 95% CI 0.26–0.38). By 
contrast, sex and type of diabetes were not found to be as-
sociated with attendance in the multivariable mixed-effects 
logistic regression analysis.
The following factors were associated with the detection 
of referable retinopathy: age; sex; ethnicity; IMD decile; dia-
betes type; and time from diagnosis of diabetes. All of these 
factors were associated with increased odds of requiring fur-
ther surveillance or referral to the hospital eye service (Table 
4). We estimated that people aged 24–29 years at registration 
were more likely to have referable retinopathy compared to 
those aged >60 years (adjusted OR 1.85, 95% CI 1.37–2.50). 
Other risk factors for referable retinopathy included type 1 
diabetes, black/minority ethnicity, and living in areas of high 
socio-economic deprivation.
3.2 | Visual impairment certification
In 2018/2019, 25 887 new certifications for sight impair-
ment and severe sight impairment in England and Wales 
were received by the Certifications Office. This corresponds 
to a rate of 44 per 100 000 population, which was similar 
to 2009/2010 (Table 5). Over the same period, the rate of 
vision impairment with diabetic eye disease as the sin-
gle main reason for certification, fell from 2.4 per 100 000 
in 2009/2010 (n = 1334) to 1.5 per 100 000 in 2018/2019 
(n = 904). Similarly, the number of new certifications with a 
single main cause of diabetic eye disease as a percentage of 
the total number of certifications fell from 5.5% in 2009/2010 
to 3.5% in 2018/2019.
Further analysis of these data based on age showed a con-
sistent downward trend for those aged ≥65 years, and a less 
pronounced reduction for those aged 35–59 years (Figure 3). 
By contrast, there was no change in certifiable vision impair-
ment for those aged <35 years over the last 10 years. For this 
group, 543 young adults were certified as sight-impaired or 
severely sight-impaired in England and Wales over the re-
porting period.
4 |  DISCUSSION
The primary aim of the present study was to investigate the 
relationship between age and attendance for diabetic eye 
screening.
Based on our analysis of Cohort A, the time interval be-
tween registration and attendance was significantly longer 
for the age group 18–34 years, with only 70% meeting the 
NDESP standard for routine annual screening. More signifi-
cantly, approximately 20% of young adults were unscreened 
at the end of the 40-month reporting period. These results 
mirror the findings of Scanlon et al.,12 who similarly found 
that this group were the least likely to attend promptly for 
first screening. A longer interval between registration and 
screening increases the risk of developing sight-threatening 
diabetic retinopathy. Scanlon et al. reported that the odds of 
detecting sight-threatening retinopathy were over four times 
higher in those whose screening was delayed by 36 months 
or longer.12 In 2017, the NDESP introduced a new quality 
standard that requires DESPs to report annually the propor-
tion of those who had not attended for screening in the previ-
ous 3 years. These data are valuable in identifying high-risk 
F I G U R E  1  Kaplan–Meier plot of time to first screening event after registration by age strata: 12–17 years, 18–34 years, 35–59 years and 
≥60 years (Cohort A).
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populations that require targeted interventions to facilitate 
screening uptake.
The larger sample size of Cohort B provided an opportu-
nity to undertake a more granular analysis of the relationship 
between age and ongoing screening attendance. Although the 
overall screening uptake for this cohort was high (~95%), there 
was considerable variability in uptake between age groups, 
with young adults being the least likely to attend for screen-
ing. Despite participants aged <35 years accounting for <4% 
of the total cohort, this group had a disproportionately higher 
rate of non-attendance (9.3%). Non-attendance was signifi-
cantly higher for those aged 24–29 years. The odds of attend-
ing a screening event in this group were approximately 70% 
lower than in the reference group of people aged >60 years, 
after controlling for other factors. Significantly, young adults 
were also more likely to present with referable retinopathy. 
Several published health equity audits over the past two 
decades have similarly reported on the relative lack of en-
gagement of young people with the DESP.11,13,18,19 Regional 
DESPs report performance against the NDESP standard for 
uptake of routine digital screening as an aggregated annual 
figure. Based on the most recent annual report, only two of 
the regional DESPs in England supplying data failed to meet 
the ‘acceptable’ performance target of 75% uptake, with 22 
meeting the ‘achievable’ 85% target.9 However, these figures 
mask the heterogeneity in screening uptake between demo-
graphic groups. Theoretically, robust failsafe systems are in 
place to identify non-attenders, auditing post office returns, 
sending further invitations and executing local initiatives to 
improve uptake.20 Based on the evidence from the present 
study, there is still a major issue with sub-optimal attendance 
in young adults, which highlights the need for policy initia-
tives and tailored interventions to address these inequities. 
These could include reporting of attendance by age group 
and performance indicators for screening uptake being tai-
lored to the risk of developing sight-threatening retinopathy.
The secondary objective of the present study sought to 
identify other covariates associated with diabetic eye screen-
ing uptake. Data on demographic factors, for example, sex, 
ethnicity, type and duration of diabetes and social deprivation 
(IMD deciles), were extracted for each cohort and tested for 
their association with screening attendance. We identified a 
consistent socio-economic gradient in uptake, with the odds 
of non-attendance in those living in the most deprived areas 
(IMD deciles 1–2) being 27% higher than in the least deprived 
areas (IMD deciles 7–10). Although minority ethnic groups 
(including both South Asian and African/Afro-Caribbean 
people) have a greater likelihood of developing retinopathy 
than those of white ethnicity,21 information on the impact of 
ethnicity on screening attendance is sparse. This is largely 
due to the non-availability of ethnicity data in screening reg-
isters.13 In our large ethnically diverse sample, self-reported 
T A B L E  2  Demographic characteristics of all people in the 
Routine Digital Screening pathway (Cohort B; N = 291 296).
Characteristic Missingness, n (%)
Mean (sd) age at 1 February 2018, 
years
61.8 (14) -
Age 1 February 2018, n (%)
12–17 years 1366 (0.5) -
18–23 years 1869 (0.6)
24–29 years 2923 (1.0)
30–35 years 5562 (1.9)
36–41 years 11 690 (4.0)
42–47 years 21 757 (7.5)
48–53 years 34 569 (12)
54–59 years 44 628 (15)
≥60 years 166 932 (57)
Total, N = 291 296
Sex
Female 132 647 (46) 2909 (1.0)
Male 155 717 (54)
Unknown 23 (0.0)
Total, N = 288 387
Ethnicity
White 95 192 (40) 54 554 (18.7)
Mixed 3334 (1.4)
Asian or Asian British 63 897 (27)
Black or Black British 38 520 (16)
Other/Not stated/Unknown 35 799 (15)
Total, N = 236 742
National IMD decile groups
(group 1 most deprived, group 4 
least deprived)
Group 1(deciles 1–2) 122 055 (42) 599 (0.2)
Group 2 (deciles 3–4) 84 124 (29)
Group 3 (deciles 5–6) 42 017 (15)
Group 4 (deciles 7–10) 42 501 (15)
Total, N = 290 697
Diabetes type
Type 1 9880 (4.6) 78 521 (27.0)
Type 2 199 988 (94)
Not specified 2633 (1.2)
Other 274 (0.2)
Total, N = 212 775
Time from diagnosis of diabetes to 1 
February 2018
<5 years 61 220 (32) 99 543 (34.2)
5–9 years 55 901 (29)
10–19 years 59 887 (31)
≥20 years 14 745 (7.7)
Total, N = 191 753
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ethnicity was available for approximately 80% of partici-
pants. Using white ethnicity as the reference value, Asian or 
Asian British people were more likely to attend screening, 
and those with mixed ethnicity were the least likely to attend. 
There was no statistical difference in attendance for those of 
black or black British ethnicity. Significantly, attendance for 
initial screening within 15 months of registration strongly in-
fluenced subsequent screening behaviour; those who failed to 
attend their initial screening appointment had an 83% lower 
odds of attending subsequently than those who attended their 
initial appointment.
Previous studies have retrospectively analysed temporal 
trends in new certifications of vision impairment in England 
and Wales attributable to diabetic eye disease.4,22,23 In 2014, 
Liew et al.22 reported that, for the first time in at least five 
decades, diabetic retinopathy/maculopathy was no longer the 
leading cause of certifiable blindness among working age 
adults. The present analysis shows that, despite the increas-
ing number of people with diabetes, this downward trend 
has continued, with 3.5% of new certifications reporting di-
abetic eye disease as the main cause of vision impairment 
in 2019 compared to 5.5% in 2009. There are a number of 
possible explanations for the observed trend, including: the 
establishment of NDESPs across the UK in 2008, the impact 
of the Quality and Outcomes Framework on diabetes care 
that incentivised and resourced general practices to meet key 
performance indicators in diabetes, and the development of 
new treatments for diabetic maculopathy. The present study 
reports, for the first time, the number of new certifications 
with a single main cause of diabetic eye disease based on age 
of the population. We identified a marked downward trend 
over the period 2009 to 2019 for those aged ≥65 years, with 
a less pronounced reduction for those aged 35–59 years. By 
contrast, certifications in those aged <35 years over the same 
period were unchanged. Whilst it is not possible to estab-
lish a causal relationship between the development of vision 
impairment and non-attendance for diabetic eye screening, 
given the greater risk of developing sight-threatening reti-
nopathy in this group, it is likely that failure to attend would 
delay access to timely and effective treatment for diabetic eye 
disease.
The main strength of the present study is the use of a 
large up-to-date dataset from a representative multi-ethnic 
urban population, with catchment areas that represent the 
UK’s diversity in terms of vulnerable groups, ethnicity and 
deprivation. For example, in the Birmingham catchment area 
there was representation from the first to 10th IMD deciles, 
with an individual range in rank nationally by Lower Layer 
Super Output Area from 38 to 32703. Although the dataset 
was sufficiently large to identify patient-level factors that in-
fluence screening uptake, the lack of geographical variation 
in included rural populations and the inclusion of different 
methods of screening, for example, mobile eye screening ser-
vices, prevented the analysis of these covariates.
For the DESPs in England, the recording of certain infor-
mation is mandatory, such as the person's name, date of birth, 
contact details, NHS number, general practitioner, invitation 
date and screening result. However, the availability of infor-
mation on ethnicity, type and date of diagnosis of diabetes 
varies among programmes. From our datasets, which repre-
sent three large urban DESPs in England, we found evidence 
of significant amounts of missing data and variability in data 
quality among programmes. Important information was often 
not available. For example, for Cohort B, the type and duration 
F I G U R E  2  Stacked bar plot of all people eligible for Routine Digital Screening from three Diabetic Eye Screening Programmes, by age 
group and attendance.
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of diabetes were missing for 27% and 34% of records, re-
spectively. Important clinical and lifestyle information is not 
generally available to the DESP and the ‘General Practice to 
T A B L E  3  Mixed-effects logistic regression analysis with 
dependent attendance (N = 276 335) vs non-attendance (N = 14 960) 
by the below exploratory factors for all people eligible for screening in 
Routine Digital Screening (Cohort B).
Exploratory factor
Univariate
OR (95% CI)
Multivariable
OR (95% CI)
Age at 1 February 2018
12–17 years 0.73 (0.57–0.95) 1.02 (0.71–1.48)
18–23 years 0.28 (0.24–0.33) 0.33 (0.26–0.42)
24–29 years 0.25 (0.22–0.29) 0.31 (0.26–0.38)
30–35 years 0.27 (0.25–0.30) 0.36 (0.32–0.41)
36–41 years 0.41 (0.38–0.44) 0.50 (0.46–0.55)
42–47 years 0.54 (0.51–0.58) 0.64 (0.59–0.69)
48–53 years 0.65 (0.62–0.69) 0.73 (0.68–0.79)
54–59 years 0.81 (0.76–0.85) 0.87 (0.82–0.93)
≥60 years Reference Reference
Sex
Female 1.05 (1.01–1.08) 0.99 (0.95–1.04)
Male Reference Reference
Ethnicity
White Reference Reference
Mixed 0.63 (0.55–0.73) 0.80 (0.67–0.96)
Asian or Asian British 1.19 (1.13–1.25) 1.29 (1.21–1.37)
Black or black British 1.01 (0.96–1.08) 1.03 (0.96–1.11)
Other/not stated/
unknown
0.82 (0.75–0.90) 1.04 (0.92–1.17)
National IMD decile 
groups (group 1 
most deprived, group 
4 least deprived)
Group 1 (deciles 1–2) 0.75 (0.69–0.82) 0.73 (0.65–0.82)
Group 2 (deciles 3–4) 0.80 (0.74–0.87) 0.78 (0.70–0.88)
Group 3 (deciles 5–6) 0.91 (0.83–0.99) 0.86 (0.76–0.97)
Group 4 (deciles 
7–10)
Reference Reference
Diabetes type
Type 1 0.58 (0.53-0.64) 1.13 (0.99-1.28)
Type 2 Reference Reference
Attendance at first screening within 15 months
No 0.07 (0.07-0.07) 0.17 (0.16-0.18)
Yes Reference Reference
Time from diagnosis of diabetes to 1 February 2018
<5 years Reference Reference
5–9 years 1.40 (1.33–1.48) 1.21 (1.15–1.29)
10–19 years 1.69 (1.61–1.79) 1.63 (1.54–1.74)
≥20 years 1.58 (1.45–1.73) 1.58 (1.42–1.75)
Abbreviation: IMD, Index of Multiple Deprivation; OR, odds ratio.
Data are ORs of attendance at routine diabetic screening by putative risk factors 
with 95% CI.
T A B L E  4  Mixed-effects logistic regression analysis with 
dependent referable retinopathy (N = 6986) vs no referral (N = 215 
559) for all people eligible for screening in Routine Digital Screening.
Exploratory factor
Univariate
OR (95% CI)
Multivariable
OR (95% CI)
Age at 1 February 2018
12–17 years 0.087 (0.028–0.27) 0.22 (0.07–0.68)
18–23 years 0.69 (0.47–1.00) 1.22 (0.78–1.90)
24–29 years 1.29 (1.02–1.63) 1.85 (1.37–2.50)
30–35 years 1.14 (0.96–1.36) 1.53 (1.19–1.97)
36–41 years 1.20 (1.06–1.35) 2.12 (1.80–2.49)
42–47 years 1.03 (0.94–1.14) 1.82 (1.60–2.07)
48–53 years 1.05 (0.98–1.14) 1.68 (1.52–1.87)
54–59 years 1.01 (0.94–1.08) 1.46 (1.33–1.61)
≥60 years Reference Reference
Sex
Female 0.82 (0.78–0.86) 0.81 (0.76–0.87)
Male Reference Reference
Ethnicity
White Reference Reference
Mixed 1.40 (1.09–1.80) 1.24 (0.91–1.69)
Asian or Asian British 1.52 (1.41–1.64) 1.57 (1.43–1.72)
Black or Black British 1.50 (1.38–1.64) 1.65 (1.49–1.83)
Other/not stated/
unknown
2.47 (2.28–2.67) 1.78 (1.57–2.02)
National IMD decile 
groups
(group 1 most deprived, 
group 4 least deprived)
Group 1 (deciles 1–2) 1.29 (1.18–1.40) 1.42 (1.25–1.62)
Group 2 (deciles 3–4) 1.19 (1.09–1.30) 1.35 (1.19–1.54)
Group 3 (deciles 5–6) 1.10 (1.00–1.22) 1.20 (1.04–1.38)
Group 4 (deciles 7–10) Reference Reference
Time from diagnosis of 
diabetes to 01/02/2018
<5 years Reference Reference
5–9 years 1.59 (1.43–1.77) 1.70 (1.52–1.90)
10–19 years 3.22 (2.93–3.55) 3.74 (3.37–4.15)
≥20 years 7.75 (6.95–8.63) 8.47 (7.48–9.59)
Diabetes type
Type 1 2.89 (2.62–3.19) 1.74 (1.51–2.02)
Type 2 Reference Reference
Abbreviation: IMD, Index of Multiple Deprivation; OR, odds ratio.
Odds ratios of referable retinopathy in patients attending routine diabetic 
screening by putative risk factors.
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Diabetic Retinopathy Screening’ system does not currently 
provide relevant clinical data that would be valuable for fail-
safe processes in those at higher risk of sight loss. In the future, 
these data could enable personalized risk-based screening.24
Whilst the NDESP has been successful in ensuring that 
the vast majority of the eligible population receive retinopa-
thy screening in a timely manner, there is considerable vari-
ation in uptake rates among age groups. Young adults with 
diabetes experience a variety of social and psychological 
barriers that often lead to poor glycaemic control and non-en-
gagement with health services.25 The present study provides 
further evidence that a significant minority of young adults 
are still not engaging with diabetic eye screening services 
and were more likely to present with sight-threatening dia-
betic retinopathy. Those in the age group 18–34 years were 
the least likely to attend promptly for screening after initial 
registration and also have the lowest uptake rates at annual 
screening appointments. This is likely to have major conse-
quences in terms of the risk of developing sight-threatening 
diabetic eye disease. Other factors associated with lower 
uptake rates include living in areas of high socio-economic 
deprivation and failure to attend for screening in the first 
15 months post-registration. There is an urgent need for fur-
ther research to understand patient- and system-level barriers 
T A B L E  5  New certifications for sight impairment and severe sight impairment due to diabetic retinopathy in those persons with known 
diabetes in England and Wales between 2009 and 2019.
Year Total
Diabetic eye disease: 
single main cause
Diabetic eye disease: single 
main cause, % of total
Diabetic eye disease: single 
main cause, n per 100 000
2009/2010 24 231 1334 5.5 2.4
2010/2011 23 926 1261 5.3 3.1
2011/2012 25 079 1329 5.3 2.3
2012/2013 24 009 1194 5.0 2.1
2013/2014 24 213 1066 4.4 1.8
2014/2015 24 260 994 4.1 1.7
2015/2016 24 361 869 3.6 1.5
2016/2017 24 874 903 3.6 1.5
2017/2018 24 299 793 3.3 1.3
2018/2019 25 887 904 3.5 1.5
F I G U R E  3  New certifications for sight impairment and severe sight impairment attributable to diabetic retinopathy as the single main cause 
in England and Wales from 2009 to 2019.
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to and enablers of attendance for diabetic eye screening 
amongst young adults in order to inform policy and develop-
ment of targeted strategies to increase attendance.
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